Ozanimod in the therapy of relapsing-remitting multiple sclerosis – case series Case report
Article Sidebar
Published:
Jun 20, 2022
Keywords:
multiple sclerosis, sphingosine-1-phosphate receptor, ozanimod
Main Article Content
Abstract
Multiple sclerosis is a chronic, inflammatory, autoimmune and neurodegenerative disease of the central nervous system, characterized by the presence of demyelinating lesions disseminated in space and time. Sphingosine-1-phosphate receptor modulators are one of the therapeutic options for disease modifying therapies. Ozanimod is a novel selective sphingosine-1-phosphate modulator with proven high efficacy and safety of treatment. The presented cases of patients treated with ozanimod confirm the previous results of studies on the efficacy and safety of ozanimod in the population of patients with early and advanced relapsing-remitting multiple sclerosis.
Article Details
How to Cite
Bonek , R. (2022). Ozanimod in the therapy of relapsing-remitting multiple sclerosis – case series. Medycyna Faktow (J EBM), 15(2(55), 236-239. https://doi.org/10.24292/01.MF.0222.18
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Filippi M, Bar-Or A, Piehl F et al. Multiple sclerosis. Nat Rev Dis Primers. 2018; 4(1): 43.
2. Thompson AJ, Baranzini SE, Geurts J et al. Multiple sclerosis. Lancet. 2018; 391(10130): 1622-36.
3. Walton C, King R, Rechtman L et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS. Mult Scler J. 2020; 26(14): 1816-21.
4. Brola W, Sobolewski P, Flaga S et al. Increasing prevalence and incidence of multiple sclerosis in Poland. Neurol Neurochir Pol. 2017; 51: 82-5.
5. Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: Clinical aspects. Curr Opin Neurol. 2018; 31: 752-9.
6. Bonek R (ed). Stwardnienie rozsiane. Od chemokin do przeciwciał monoklonalnych. PZWL, Warszawa 2019: 9-10.
7. Obinata H, Hla T. Sphingosine 1-phosphate and inflammation. Int Immunol. 2019; 31(9): 617-25.
8. McGinley MP, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions. Lancet. 2021; 398(10306): 1184-94.
9. Comi G, Kappos L, Selmaj KW et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019; 18(11): 1009-20.
10. Cohen JA, Comi G, Selmaj KW et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 2019; 18(11): 1021-33.
11. Swallow E, Patterson-Lomba O, Yin L et al. Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis. J Comp Eff Res. 2020; 9(4): 275-85.
2. Thompson AJ, Baranzini SE, Geurts J et al. Multiple sclerosis. Lancet. 2018; 391(10130): 1622-36.
3. Walton C, King R, Rechtman L et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS. Mult Scler J. 2020; 26(14): 1816-21.
4. Brola W, Sobolewski P, Flaga S et al. Increasing prevalence and incidence of multiple sclerosis in Poland. Neurol Neurochir Pol. 2017; 51: 82-5.
5. Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: Clinical aspects. Curr Opin Neurol. 2018; 31: 752-9.
6. Bonek R (ed). Stwardnienie rozsiane. Od chemokin do przeciwciał monoklonalnych. PZWL, Warszawa 2019: 9-10.
7. Obinata H, Hla T. Sphingosine 1-phosphate and inflammation. Int Immunol. 2019; 31(9): 617-25.
8. McGinley MP, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions. Lancet. 2021; 398(10306): 1184-94.
9. Comi G, Kappos L, Selmaj KW et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019; 18(11): 1009-20.
10. Cohen JA, Comi G, Selmaj KW et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 2019; 18(11): 1021-33.
11. Swallow E, Patterson-Lomba O, Yin L et al. Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis. J Comp Eff Res. 2020; 9(4): 275-85.